Juno Therapeutics, Inc. (NASDAQ:JUNO) will issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million for the quarter, compared to the consensus estimate of $15.59 million. During the same period in the prior year, the firm posted ($0.64) earnings per share. The business’s revenue was down 22.8% on a year-over-year basis. On average, analysts expect Juno Therapeutics to post $-3.53 EPS for the current fiscal year and $-3.86 EPS for the next fiscal year.

Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) opened at 46.29 on Tuesday. Juno Therapeutics, Inc. has a 12-month low of $17.52 and a 12-month high of $48.14. The company’s market capitalization is $4.86 billion. The stock’s 50 day moving average is $43.87 and its 200-day moving average is $31.99.

Several research firms recently weighed in on JUNO. Citigroup Inc. raised their target price on shares of Juno Therapeutics to $59.00 and gave the company a “buy” rating in a research note on Tuesday. Vetr raised shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 target price for the company in a research note on Monday, August 14th. Cowen and Company reaffirmed a “buy” rating and set a $49.00 target price on shares of Juno Therapeutics in a research note on Friday. Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Morgan Stanley raised their target price on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, August 7th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $40.45.

ILLEGAL ACTIVITY NOTICE: “Juno Therapeutics, Inc. (JUNO) Scheduled to Post Quarterly Earnings on Tuesday” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/31/juno-therapeutics-inc-juno-scheduled-to-post-quarterly-earnings-on-tuesday.html.

In related news, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Bernard J. Cassidy sold 28,000 shares of Juno Therapeutics stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the sale, the general counsel now owns 55,970 shares of the company’s stock, valued at approximately $2,514,172.40. The disclosure for this sale can be found here. Insiders have sold a total of 85,004 shares of company stock valued at $3,551,561 in the last quarter. 15.26% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in Juno Therapeutics stock. The Manufacturers Life Insurance Company boosted its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 7.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,405 shares of the biopharmaceutical company’s stock after buying an additional 228 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Juno Therapeutics were worth $102,000 as of its most recent SEC filing. 67.18% of the stock is currently owned by institutional investors and hedge funds.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Earnings History for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.